Ann: UK Regulatory Authorisation to Proceed with Phase 2 Trial, page-15

Thanks, Skint. There is no doubt, PBT2 will help the existing antibiotics to kill many, really many different antibiotic-resistant bacteria. The microbiologist experts I have been able to consult agree with me and one of the inventors of the patent has told my friend in an e-mail that clinical evidence ( as now is happening with otitis media ? ) will increase the commercialization value so much that it is worth waiting. When ATH will get to that phase the market value will jump, jump and jump so that even the widows and orphans would be happy but perhaps even those who do not become orphans and widows because of PBT2 helping in previously deadly infections.

When Stamler will tell about PBT2 is not sure, but it would be a good time to do just very soon to get over the one-dollar before the deadline. I am sure the market would like that kind of announcement.